Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo has announced that the US District Court of New Jersey has denied Connetics's motion for a preliminary injunction related to the company's Clobetasol Propionate Foam, the AB-rated generic equivalent to Connetics's Olux Foam and has lifted the temporary restraints that have prevented Perrigo from launching the product.
Subscribe to our email newsletter
The Court also denied Perrigo’s motion for summary judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set. With the temporary restraints lifted, Perrigo has commenced launching the product. As the first filer, this commences its 180 days of generic exclusivity.
Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp.
Joseph Papa, chairman and CEO of Perrigo, said: “We are excited about the launch of Clobetasol Foam, which reflects our on-going efforts to make quality healthcare more affordable for our customers.”